The placebo response rate in irritable bowel syndrome and inflammatory bowel disease

Digestive Diseases

Volumn 27, Issue SUPPL. 1, 2010, Pages 68-75

  Sands, Bruce E ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

Crohn's disease; Inflammatory bowel disease; Irritable bowel syndrome; Placebo response; Ulcerative colitis

Indexed keywords

C REACTIVE PROTEIN; CERTOLIZUMAB PEGOL; PLACEBO;

ABDOMINAL PAIN; ACUPUNCTURE; ARTHRALGIA; ARTHRITIS; CONFERENCE PAPER; DIARRHEA; ENTERITIS; ERYTHEMA NODOSUM; FECES; FOLLOW UP; HEMATOCRIT; HUMAN; IRITIS; IRRITABLE COLON; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PYODERMA GANGRENOSUM; QUALITY OF LIFE; RECTUM HEMORRHAGE; REMISSION; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT RESPONSE; UVEITIS; WELLBEING;

COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PLACEBOS;

EID: 77950817606     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000268123     Document Type: Conference Paper

References (22)

1. Schulz KF, Chalmers I, Hayes RJ, Altman DG: Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA 1995; 273: 408-412.
2. Hrobjartsson A, Gotzsche PC: Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344: 1594-1602.
3. Bernstein CN: The placebo effect for gastroenterology: tool or torment. Clin Gastroenterol Hepatol 2006; 4: 1302-1308.
4. Musial F, Klosterhalfen S, Enck P: Placebo responses in patients with gastrointestinal disorders. World J Gastroenterol 2007; 13: 3425-3429.
5. Hoffman GA, Harrington A, Fields HL: Pain and the placebo: what we have learned. Perspect Biol Med 2005; 48: 248-265.
6. Vase L, Robinson ME, Verne GN, Price DD: Increased placebo analgesia over time in irritable bowel syndrome (IBS) patients is associated with desire and expectation but not endogenous opioid mechanisms. Pain 2005; 115: 338-347.
7. Kaptchuk TJ: The placebo effect in alternative medicine: can the performance of a healing ritual have clinical significance? Ann Intern Med 2002; 136: 817-825.
8. Pitz M, Cheang M, Bernstein CN: Defining the predictors of the placebo response in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3: 237-247.
9. Patel SM, Stason WB, Legedza A, Ock SM, Kaptchuk TJ, Conboy L, et al: The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil 2005; 17: 332-340.
10. Dorn SD, Kaptchuk TJ, Park JB, Nguyen LT, Canenguez K, Nam BH, et al: A meta-analysis of the placebo response in complementary and alternative medicine trials of irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 630-637.
11. Kaptchuk TJ, Kelley JM, Conboy LA, Davis RB, Kerr CE, Jacobson EE, et al: Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008; 336: 999-1003.
12. Conboy LA, Wasserman RH, Jacobson EE, Davis RB, Legedza AT, Park M, et al: Investigating placebo effects in irritable bowel syndrome: a novel research design. Contemp Clin Trials 2006; 27: 123-134.
13. Best WR, Becktel JM, Singleton JW: Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979; 77: 843-846.
14. Best WR, Becktel JM, Singleton JW, Kern F, Jr: Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-444.
15. Sandler RS, Jordan MC, Kupper LL: Development of a Crohn's index for survey research. J Clin Epidemiol 1988; 41: 451-458.
16. Su C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD: A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004; 126: 1257-1269.
17. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, et al: A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-818.
18. Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al: Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med 2007; 357: 239-250. (Pubitemid 47080388)
19. D'Haens G, Sandborn WJ, Feagan BG, Geboes K, Hanauer SB, Irvine EJ, et al: A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007; 132: 763-786.
20. Schroeder KW, Tremaine WJ, Ilstrup DM: Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. N Engl J Med 1987; 317: 1625-1629.
21. Su C, Lewis JD, Goldberg B, Brensinger C, Lichtenstein GR: A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology 2007; 132: 516-526.
22. Garud S, Brown A, Cheifetz A, Levitan EB, Kelly CP: Meta-analysis of the placebo response in ulcerative colitis. Dig Dis Sci 2008; 53: 875-891.